AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04127019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide chemotherapy (injection)
Study NCT02667418 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin
Description: 125 mg PO for times daily for 10 days
Study NCT04127019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin chemotherapy (injection)
Study NCT04127019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil chemotherapy (injection)
Study NCT03551769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard meal
Description: standard meal
Study NCT03551769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal
Description: high-fat meal
Study NCT03319719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero® Balance with integral lidocaine
Description: Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
Study NCT03319719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Belotero® Balance
Description: Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
Study NCT03551769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overnight fast
Description: fasting for at least 9 hours
Study NCT04615143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w). After 2 cycles of Tislelizumab and evaluation of resectability, patients will receive surgery in 6 weeks after enrollment. Patients will receive Tislelizumab for 1 year (200mg, iv, q3w, 17 cycles) in 4-6 weeks after surgery.
Study NCT04615143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with Levatinib
Description: Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w); Lenvatinib from Day1 to Day 28 (8/12mg qd). After neoadjuvant treatment and evaluation of resectability, patients will receive surgery in 6weeks after enrollment. Patients will receive Tislelizumab combined with Lenvatinib for 1 year in 4-6 weeks after surgery.
Study NCT04108208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.
Study NCT04108208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally.
Study NCT04108208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation Therapy (ADT)
Description: Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
Study NCT04108208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen-deprivation Therapy (ADT)
Description: Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
Study NCT02175394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon®
Study NCT02175394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Study NCT02175394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Study NCT04146493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for Heparin-binding protein measurement
Description: Blood samples before and after given heparin
Study NCT02587598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth.
Study NCT02587598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-DAC (Intermediate dose cytarabine)
Description: Cytarabine dose will be 1 g/m\^2. Cytarabine will be administered as an intravenous (IV) infusion.
Study NCT02587598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine dose will be 75 mg/m\^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).
Study NCT02587598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.
Study NCT03104049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular taping
Description: NMT applications:~1. rhomboid major muscle~2. muscles abdominals~3. spinal muscles~4. pectoralis major muscles~5. gastrocnemius muscle~6. upper trapezius muscle~7. anterior muscles of the neck
Study NCT03670524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Greenness as a therapeutic intervention
Description: Greenness to be used as a therapeutic intervention
Study NCT03361748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: : bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
Study NCT03633708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etelcalcetide
Description: Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
Study NCT03633708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
Study NCT03374501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugardown™
Description: Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)
Study NCT03374501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soft drink
Description: Test food #1: 495.0 g Sprite™ soft drink consumed with 250 mL water (repeated twice)
Study NCT01219764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
Description: Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
Study NCT01219764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
Description: Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
Study NCT00738790 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course of radiotherapy
Description: 5 x 5 Gy plus boost 4 Gy
Study NCT00738790 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiochemotherapy
Description: 28 x 1,8Gy plus boost 3 x 1,8 Gy with three 2-days cycles of chemotherapy during weeks 1, 3 and 5 of irradiation (the each cycle consisted of leukovorin 20 mg/m2 per day and 10-20 minutes later of 5-fluorouracil 400 mg/m2 per day, both administrated as rapid intravenous infusion)
Study NCT02627326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: periodontal surgery in the form of open flap debridement was done in both the groups
Study NCT00683124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan and nebivolol
Description: Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.~Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
Study NCT00683124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
Study NCT00683124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
Study NCT04287855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab by IV route - Cycle 1 : 10mg/kg on days 1, 8, 15 and 22 per 28 days cycle. After cycle 1 : 10mg/kg on days 1 and 15 per 28 days cycle
Study NCT04287855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib by IV route - Cycle 1 : 20/27 mg/m² on days 1-2, 8-9, 15-16 per 28 days cycle. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
Study NCT04287855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide by oral route - Cycle 1-2 : 3mg on days 1 to 21 per 28 days cycle. After cycle 2 : 4mg on days 1 to 21 per 28 days cycle.
Study NCT04287855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone by oral route - Cycle 1-13 : 40/20 mg on days 1, 8, 15 and 22. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
Study NCT04144582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Combined With Docetaxel Monotherapy
Description: Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w
Study NCT04366297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous access
Description: obtaining intravascular access using a standard intravenous cannula
Study NCT04366297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraosseous access
Description: obtaining intravascular access using a ready intravenous NIO needle set
Study NCT01319474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Whole-leg compression ultrasound
Description: Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
Study NCT00761670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amisulpride and risperidone
Description: amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
Study NCT01855243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regular insulin
Study NCT01855243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 70/30 insulin
Study NCT00693576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 20 mg simvastatin daily
Study NCT00384059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
Study NCT00384059 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7vPnC
Description: Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
Study NCT00384059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediacel
Description: concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
Study NCT00384059 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel
Description: concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
Study NCT00384059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C
Description: concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
Study NCT00384059 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NeisVac-C
Description: concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
Study NCT00384059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menitorix
Description: concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
Study NCT00384059 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix
Description: concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
Study NCT03146039 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: Whole pelvis radiation therapy will be delivered according to institutional standard of care.~SBRT is delivered with 5 fractions of 5.5-8 Gy prescribed to the high-risk CTV, with dose constraints identical to those for high dose rate, volume-directed brachytherapy. The patient will undergo arc therapy with a minimum of two arcs. On-line kV CBCT will be used to verify the isocenter prior to each arc delivery. Patients will be resimulated for SBRT boost planning.
Study NCT02978001 — intervention group
Intervention type: OTHER
Intervention: Stabile Isotope tracers
Description: Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
Study NCT04002804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells Vaccine
Description: Right after the surgical resection of the recurrent tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Starting at week 3, immunotherapy will include 4 bi-weeekly vaccinations first (injections I, II, III, IV), two further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) two months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only.~Vaccine doses will be injected in the forearm of the patient.
Study NCT04794101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic: AAV5-hRKp.RPGR Intermediate Dose
Description: Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
Study NCT04794101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic: AAV5-hRKp.RPGR Low Dose
Description: Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
Study NCT01855243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Study NCT01855243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glulisine
Study NCT02938988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy
Description: Described in arm/group
Study NCT02938988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planning
Description: Described in arm/group
Study NCT02938988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Described in arm/group
Study NCT02938988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: red laser
Description: 658nm; 0.1W; 2229J/cm², 10s per point
Study NCT02938988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylene blue dye
Study NCT01914146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Insulin
Description: Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
Study NCT01914146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Insulin
Description: Study session will occur prior to initiation of insulin therapy.
Study NCT04028869 — intervention group
Intervention type: DRUG
Intervention: Glycyrrhizic acid preparation
Description: To analyze the clinical effect of glycyrrhizic acid preparation for autoimmune liver disease for 144 weeks and the safety during treatment
Study NCT00974467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After The Injury website
Description: Parents participate in a web-based prevention intervention, which provides education and tips specific to coping with a child's injury.
Study NCT00974467 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Usual hospital care provided.
Study NCT01927003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal digito-metacarpal flap
Description: The dorsal digito-metacarpal flap is a vascular island flap based on the dorsal digital artery and dorsal metacarpal artery. It has a longer vascular pedicle and provides tissue coverage of similar quality as that of normal glabrous skin but not sacrifice the digital artery.
Study NCT02669901 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Naloxone Auto-Injector
Description: Naloxone auto-injector is FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.
Study NCT01552668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: Receive 200 mg of fidaxomicin twice daily
Study NCT01552668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive Placebo twice daily
Study NCT01292317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of intravenous volume
Description: weight based intravenous application of volume
Study NCT01292317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral fluid application
Description: oral fluid application
Study NCT03502642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: A10ml bolus of normal saline were administered in the wound catheter after skin closure then an infusion of normal saline at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
Study NCT04909632 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid chromatography-mass spectrometry (LC-MS) analysis
Description: The data were acquired by UNIFI software (Waters) and processed by UNIFI and Progenesis QI software. Omics analysis methods, such as principal component analysis (PCA), partial least squares-discriminate analysis (PLS-DA), and orthogonal partial least squares-discriminate analysis (OPLS-DA), were employed to identify the biochemical patterns in tongue coating samples and suggest variables that can be used as biomarkers for diabetes and pre-diabetes.
Study NCT01823003 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 34 Gy in a single fraction
Description: 34 Gy in a single fraction in case of Distance to chest wall > 1 cm, tumour size \< 2 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
Study NCT01823003 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 54Gy 18Gy/fr. x 3 fractions
Description: 54Gy administered in 3 fractions of 18Gy in case of distance to chest wall > 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
Study NCT01823003 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60Gy (12 x 5 fr.s)
Description: 50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall \< 1 cm, tumour size \< 5 cm and distance to main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
Study NCT01823003 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60Gy (7.5Gy x 8fr.)
Description: 60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size \< 5 cm and distance to the main bronchus \< 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
Study NCT00365352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512 600MG
Description: XP13512 600MG ONCE DAILY
Study NCT00365352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512 1200MG
Description: XP13512 1200MG ONCE DAILY
Study NCT00365352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: PLACEBO ONCE DAILY